Integrase strand transfer inhibitor-associated diabetes mellitus: A case report

Peter S. Fong, Devon M. Flynn, Christopher D. Evans, Philip (Todd) Korthuis

Research output: Contribution to journalReview article

8 Scopus citations

Abstract

Integrase strand transfer inhibitors (INSTIs) have become integral antiretroviral therapy (ART) agents for treating HIV infection. We report the case of a 44-year-old male with a history of hemophilia A who developed diabetes mellitus four months after switching from abacavir, lamivudine, and efavirenz to abacavir, lamivudine, and raltegravir. Hemoglobin A1C normalized without further need for exogenous insulin after raltegravir was switched back to efavirenz. In this case report, we will review a possible mechanism for INSTI-induced hyperglycemia and/or diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)626-628
Number of pages3
JournalInternational Journal of STD and AIDS
Volume28
Issue number6
DOIs
Publication statusPublished - May 1 2017

    Fingerprint

Keywords

  • diabetes mellitus
  • HIV
  • Integrase inhibitors
  • raltegravir

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this